Home>Topics>Drug Companies

Drug Companies

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
  1. Are People Too Concerned About Orexigen's Contrave Label?

    Headlines

    Sun, 19 Oct 2014

    anti-obesity drug to be approved by the FDA in over 10 years. This is following the approval of Belviq (Arena Pharmaceuticals (NASDAQ: ARNA )) and Qsymia (Vivus (NASDAQ: VVUS )) back in 2012. Following its approval, OREX stock has

  2. Belviq Sales Dip: What To Watch For Ahead

    Headlines

    Fri, 17 Oct 2014

    By Spencer Osborne : Sales of the Arena Pharmaceuticals (NASDAQ: ARNA ) anti-obesity pill Belviq seem to be seeing some impacts of seasonality with ups and downs as the Fall weeks

  3. Tetraphase prices stock offering

    Headlines

    Fri, 17 Oct 2014

    Small cap Tetraphase Pharmaceuticals ( TTPH +14.6% ) jumps on a 3x surge in volume. Yesterday evening it announced the pricing of its public offering of 3.95M

  4. Amgen sues Sanofi and Regeneron

    Headlines

    Fri, 17 Oct 2014

    files suit in the U.S. District Court of Delaware against Sanofi (NYSE: SNY ) ( OTCQB:SNYNF ) and Regeneron Pharmaceuticals (NASDAQ: REGN ) alleging infringement on three of its patents covering monoclonal antibodies to proprotein convertase

  5. Regeneron's Eylea works better vs Avastin and Lucentis in study

    Headlines

    Fri, 17 Oct 2014

    Oct 17 (Reuters) - Regeneron Pharmaceuticals Inc said on Friday that a head-to-head study showed that its Eylea treatment for diabetic macular edema created significantly greater improvement in visual acuity compared with Genentech's Avastin and Lucentis.

  6. With Strong Corporate Partnerships, Xenon Pharmaceuticals IPO Looks Appealing

    Headlines

    Thu, 16 Oct 2014

    By Don Dion : Xenon Pharmaceuticals (Pending: XENE ) recently filed with the Securities and ..... Company Overview Located in British Columbia, Canada, Xenon Pharmaceuticals is a clinical stage biopharmaceutical company that is focused

  7. Teva Review Raises Concerns and Mesoblast Marks Time; Fair Value Unchanged

    Commentary

    Thu, 16 Oct 2014

    Mesoblast partner Teva Pharmaceuticals has announced it will discontinue or divest 14 pipeline projects, primarily in oncology and women's health, following the results

  8. Roche Holding's (RHHBY) CEO Severin Schwan on Q3 2014 Results - Earnings Call Transcript

    Headlines

    Thu, 16 Oct 2014

    2014, 08:00 AM ET Executives Severin Schwan - Chief Executive Officer Dan O'Day - Chief Operating Officer, Pharmaceuticals Roland Diggelmann - Chief Operating Officer, Diagnostics Alan Hippe - Chief Financial Officer and IT Officer Analysts

  9. Ackman: Lawyers have documents purported to show Allergan misled on Valeant

    Headlines

    Thu, 16 Oct 2014

    TORONTO (Reuters) - Billionaire investor William Ackman turned up the heat on Allergan Inc. on Thursday when he accused the Botox maker’s board of misleading investors to fend off a hostile takeover bid from Valeant Pharmaceuticals .

  10. UPDATE 2-Ackman: Lawyers have documents purported to show Allergan misled on Valeant

    Headlines

    Thu, 16 Oct 2014

    TORONTO, Oct 16 (Reuters) - Billionaire investor William Ackman turned up the heat on Allergan Inc. on Thursday when he accused the Botox maker's board of misleading investors to fend off a hostile takeover bid from Valeant Pharmaceuticals .

« Prev12345Next »
Content Partners